[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atypical-chronic-myeloid-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atypical-chronic-myeloid-leukemia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,75,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100359777","early-phase-1-hyperbaric-oxygen-therapy-and-allogeneic-peripheral-blood-stem-cell-pbsc-transplant-100359777",false,"NCT03964506","Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant","A Pilot Study to Determine the Safety and Efficacy of Incorporating Hyperbaric Oxygen Therapy Into RIC Fludarabine and Melphalan and Allogeneic Hematopoietic Stem\u002FProgenitor Transplantation","Inclusion Criteria:\n\n* Voluntary written informed consent\n* Men or women, age ≥ 18 years of age, with upper limit of 75 years old.\n* Subjects with acute myeloid leukemia (AML) or Myelodysplastic Syndrome (MDS) for cohort 1.\n* Subjects with chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), CML, chronic neutrophilic leukemia (CNL), myelofibrosis, and myelodysplastic\u002Fmyeloproliferative (MDS\u002FMPN) overlap syndrome for cohort 2.\n* Karnofsky performance status (KPS) of ≥ 70%\n* Patients should have New York Heart Association (NYHA) Functional Classification, Class I (ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain) or Class II (ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain).\n* Adequate hepatic, renal, cardiac and pulmonary function to be eligible for transplant. Minimum criteria include: Hepatic: ALT, AST \\\u003C 4x IULN and serum total bilirubin ≤ 2.0 mg\u002FdL; Renal: serum creatinine: ≤ 2.0 mg\u002FdL; Left ventricular ejection fraction ≥ 45% measured by 2D-ECHO or MUGA scan; EKG with no clinically significant arrhythmia; FEV1, FVC and DLCO ≥ 50% of predicted value (corrected to serum hemoglobin)\n* Women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days following completion of therapy. Should a woman or partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician and the investigator immediately.\n* A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)\n* Women of child-bearing potential should have a negative urine or serum pregnancy test within 4 weeks of starting preparative regimen\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Severe chronic obstructive pulmonary disease requiring oxygen supplementation\n* History of spontaneous pneumothorax, prior chest surgery requiring thoracotomy or direct chest irradiation to the lungs\n* Evidence of pneumothorax or significant pulmonary fibrosis on chest imaging within 60 days of transplant.\n* Active malignancy excluding AML, MDS, CMML, aCML CML, CNL, MF and MDS\u002FMPN overlap syndrome.\n* Active ear\u002Fsinus infection. Patients with chronic sinusitis or sinus headaches are excluded unless cleared by ear, nose, and throat specialist.\n* Recent sinus surgery (within the last 5 years).\n* Ear surgery excluding myringotomy or ear tubes\n* Subjects must agree to refrain from active tobacco or e-cigarette use 72 hours prior to transplant until complete transplant recovery. Nicotine replacement therapy is allowed.\n* Claustrophobia\n* History of recurrent seizures within 5 years of study enrollment.\n* Uncontrolled asthma\n* Uncontrolled viral or bacterial infection at the time of study enrollment\n* Active or recent (prior 6 months) invasive fungal infection without interdisciplinary (ID) consult and approval\n* Patients who had intrathecal chemotherapy within 2 weeks of starting preparative regimen or cranial irradiation within 4 weeks of starting preparative regimen","ALL","18 Years","75 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count, and incidence and severity of mucositis (inflammation of the mouth or gut) and infection. This study has two cohorts. The first cohort is subjects with acute myeloid leukemia (AML) or Myelodysplastic Syndrome (MDS). The second cohort is subjects with chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), chronic monocytic leukemia, chronic neutrophilic leukemia (CNL), myelofibrosis, and myelodysplastic\u002Fmyeloproliferative (MDS\u002FMPN) overlap syndrome. The first cohort has completed the recruitment so only the second cohort will be recruited.",[27,28,29,30,31,32,33],"Acute Myeloid Leukemia","Myelodysplastic Syndromes","Chronic Myelomonocytic Leukemia","Atypical Chronic Myeloid Leukemia","Chronic Monocytic Leukemia","Myelofibrosis","Myelodysplastic\u002FMyeloproliferative Neoplasm",[35,36],"Allogeneic transplant","Hyperbaric Oxygen","RECRUITING","2026-06-01",{"date":40,"type":41},"2026-06-03","ACTUAL",{"date":43,"type":41},"2020-07-01",{"date":45,"type":21},"2028-03-01",{"name":47,"class":48},"Omar Aljitawi","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":49},"100628997","phase-2-ropeginterferon-alfa-2b-for-the-treatment-of-myelodysplastic-syndromemyeloproliferative-neoplasm-overlap-syndromes-and-chronic-myelomonocytic-leukemia-100628997","NCT07468916","Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia","Ropeginterferon Alfa-2b for MDS\u002FMPN Overlap Syndromes, Including CMML and MDS\u002FMPN-RS-T","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age at time of consent\n* Documentation of a diagnosis of MDS\u002FMPN overlap syndrome based on World Health Organization (WHO) 2022 classification, including CMML, MDS\u002FMPN with neutrophilia, myelodysplastic\u002Fmyeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\u002FMPN-RS-T), or MDS\u002FMPN, not otherwise specified, by local pathology review, and deemed to potentially benefit from study participation by the investigator\n* Written informed consent obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study\n* Blast =\\\u003C 10% by marrow immunohistochemistry stain\n* Platelet count of \\> 50,000\u002FuL\n* Absolute neutrophils count (ANC) of \\> 1000\u002FuL\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) =\\\u003C 2\n* Serum creatinine =\\\u003C 2.5 mg\u002FdL\n* Serum direct bilirubin \\\u003C 2.0 mg\u002FdL\n* Serum transaminase \\\u003C 2.5 times the upper limit of the normal range (ULN) or \\\u003C 5 times ULN if the transaminase elevation was deemed related to the MDS\u002FMPN\n\nExclusion Criteria:\n\n* Prior therapy with interferon or pegylated interferon product, or azacitidine\n* Spleen overtly enlarged by physical exam (eg. greater than 5 fingerbreadth below costal margin)\n* Other standard (including erythropoietin-stimulating agents \\[ESA\\] or luspatercept) or experimental therapy for MDS\u002FMPN within 28 days of starting study therapy with the exception of hydroxyurea, which is allowed to continue up to 28 days after cycle 1 day 1 (C1D1) while on protocol\n* Clinically significant autoimmune disease by investigator assessment, regardless if the autoimmune phenomena is related to MDS\u002FMPN overlap syndrome\n* History of or current clinically relevant depression or anxiety per investigator's judgement. Previous suicidal ideation or attempts are not allowed to participate in interferon (IFN) therapy\n* Evidence of severe retinopathy or clinically relevant ophthalmological disorder\n* History of organ transplant\n* Pregnant or breastfeeding women\n* Active uncontrolled infection with clinical symptoms, e.g., presence of bacteria, fungal, human immunodeficiency virus (HIV), hepatitis B or C\n* Active uncontrolled thromboembolic complications or hemorrhage\n* History of any malignancy within 5 years (except adequately treated non-melanoma skin cancer, prostate cancer status post resection with an undetectable prostate-specific antigen \\[PSA\\], curative treated in-situ cancer of the cervix, ductal carcinoma in situ \\[DCIS\\] of the breast, stage 1 grade 1 endometrial carcinoma, or other solid tumors including lymphomas curatively treated with no evidence of disease for ≥ 1 year prior to study)\n* Uncontrolled active clinically significant illness that, in the investigator's opinion, may affect the patient's participation in this study\n* Active abuse of alcohol and\u002For illicit drugs",{"count":58,"type":21},35,[60],"PHASE2","This phase II trial tests the safety, best dose, and effectiveness of ropeginterferon alfa-2b for the treatment of patients with myelodysplastic syndrome\u002Fmyeloproliferative neoplasm overlap syndromes and chronic myelomonocytic leukemia. Ropeginterferon alfa-2b is a form of interferon. Interferons are a type of signaling protein normally produced by the body as part of the immune response. Interferons interfere with the division of cancer cells and can slow cancer cell growth. Ropeginterferon alfa-2b is a long-acting form of a type of interferon called interferon alfa-2b. In the body, ropeginterferon alfa-2b causes the production of proteins that modulate the immune system and have anticancer effects.",[30,29,33,63,64],"Myelodysplastic\u002FMyeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified","Myelodysplastic\u002FMyeloproliferative Neoplasm, Not Otherwise Specified","NOT_YET_RECRUITING","2026-05-05",{"date":68,"type":41},"2026-05-06",{"date":70,"type":21},"2026-09-29",{"date":72,"type":21},"2032-09-30",{"name":74,"class":48},"Jonsson Comprehensive Cancer Center",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":49},"100556319","phase-1-axatilimab-with-or-without-azacitidine-for-the-treatment-of-patients-with-advanced-phase-myeloproliferative-neoplasms-myeloproliferative-neoplasmmyelodysplastic-syndrome-overlap-or-high-risk-chronic-myelomonocytic-leukemia-100556319","NCT06523556","Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm\u002FMyelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia","Phase 1b\u002F2 Study of Axatilimab (SNDX-6352) + Azacitidine (AZA) in Advanced Phase MPN, MPN\u002FMDS Overlap or High-Risk CMML","Inclusion Criteria:\n\n* Signed informed consent must be obtained prior to participation in the study\n* Age ≥ 18 years at the date of signing the informed consent form (ICF)\n* Morphologically confirmed diagnosis of the following based on 2016 World Health Organization (WHO) classification (Arber et al 2016): Phase 1b, patients with relapsed or refractory of any of the following; phase 2, patients with newly diagnosed of any of the following:\n\n  * Chronic myelomonocytic leukemia (CMML), classified as intermediate-2, OR high-risk per the CMML Specific Prognostic Scoring System (CPSS) Molecular Model\n  * Atypical chronic myelocytic leukemia (aCML)\n  * MDS\u002FMPN unclassified (MDS\u002FMPN-U)\n  * Myeloproliferative neoplasm accelerated phase (MPN-AP)\n  * MPN-AP requires a previous diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis (PMF) with intermediate-2 or high risk disease according to International Prostate Symptom Score (IPSS) as well as progression on or failure to respond to at least one line of therapy.\n  * Myelodysplastic syndrome\u002Fmyeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\u002FMPN-RS-T) or MDS\u002FMPN with SF3B1 mutation and thrombocytosis (MDS\u002FMPN-SF3B1-T).\n  * Not suitable for immediate myeloablative\u002Fintensive chemotherapy based on investigator assessment of age, comorbidities, local guidelines, institutional practice (any or all of these)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN)\n* Total bilirubin ≤ 1.5 × ULN (except in the setting of isolated Gilbert syndrome)\n* Estimated glomerular filtration rate (eGFR) ≥ 30 mL\u002Fmin\u002F1.73m\\^2 (estimation based on Modification of Diet in Renal Disease \\[MDRD\\] formula, by local laboratory)\n* Patient is able to communicate with the investigator and has the ability to comply with the requirements of the study procedures\n* Women of childbearing potential and men, if not surgically sterilized, should use adequate contraception from 14 days prior to study entry and until 90 days after the last follow-up visit. Adequate contraception is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom\n\nExclusion Criteria:\n\n* Previous treatment for MPN or MDS\u002FMPN overlap with chemotherapy or other antineoplastic agents including lenalidomide and hypomethylating agent (HMAs) such as decitabine or azacitidine or INQOVI (oral decitabine) (patients who had up to 2 cycles of hypomethylating agents \\[HMAs\\] can be included). However, previous treatment with hydroxyurea and\u002For ruxolitinib is permitted\n* Diagnosis of acute myeloid leukemia (AML) including acute promyelocytic leukemia and extra-medullary AML based on WHO 2016 classification (Arber et al 2016)\n* Patients who are candidates for myeloablative or intensive chemotherapy treatment or who do not provide consent for this treatment\n* History of organ transplant or allogenic hematopoietic stem cell transplant\n* Participants with prior malignancy, except:\n\n  * Participants with history of adequately treated malignancy for which no anticancer systemic therapy (namely chemotherapy, radiotherapy or surgery) is ongoing or required during the course of the study.\n  * Participants who are receiving adjuvant therapy such as hormone therapy are eligible. However, participants who developed therapy related neoplasms are not eligible\n* Previous known allergy\u002Fsensitivity to components of axatilimab\n* History of acute or chronic pancreatitis\n* History of myositis",{"count":83,"type":21},52,[85,60],"PHASE1","This phase Ib\u002FII trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative neoplasm\u002Fmyelodysplastic syndrome (MPN\u002FMDS) overlap or high risk chronic myelomonocytic leukemia (CMML). Axatilimab is an antibody that is cloned from a single white blood cell that is known to be able to recognize cancer cells and block a protein on the surface of the white blood cells that may be involved in cancer cell growth. By blocking the proteins, this may slow or halt the growth of the cancer. Azacitidine is in a class of medications called antimetabolites. It works by stopping or slowing the growth of cancer cells. Giving axatilimab with or without azacitidine may be safe and effective in treating patients with advanced phase MPN, MPN\u002FMDS overlap or high risk CMML.",[30,29,33,88,89,90,91,92],"Recurrent Myelodysplastic\u002FMyeloproliferative Neoplasm","Recurrent Myeloproliferative Neoplasm","Refractory Chronic Myelomonocytic Leukemia","Refractory Myelodysplastic\u002FMyeloproliferative Neoplasm","Refractory Myeloproliferative Neoplasm","2026-03-11",{"date":95,"type":41},"2026-03-13",{"date":97,"type":41},"2024-08-02",{"date":99,"type":21},"2028-10-31",{"name":101,"class":48},"Uma Borate",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":120,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":49},"100611294","phase-2-optimization-of-post-transplantation-benadamustine-and-cyclophosphamide-in-patients-with-high-risk-myeloid-malignancies-and-a-partially-mismatched-donor-100611294","NCT07238712","Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor","Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor (APTBCy)","APTBCy","Inclusion Criteria:\n\n* Patients with indication for allogeneic hematopoietic stem cell transplantation\n* Patients with \\\u003C10\u002F10 HLA-matched related or unrelated donor available. The donor and recipient must be identical by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1.\n* Peripheral blood stem cells or bone marrow as a graft source\n* Diagnosis:\n\nAcute myeloid leukemia Chronic myeloid leukemia, Ph+ Myelodysplastic Syndromes Myeloprolipherative neoplasms - High-risk disease defined as: Acute myeloid leukemia: \\>5% of clonal blasts in bone marrow despite adequate previous induction therapy or allogeneic stem cell transplantation Myelodysplastic Syndrome: \\>5% of blasts despite previous therapy Myeloid malignancy with with -7 or complex karyotype, or p53 mutation regardless of blast count in bone marrow Treatment-related myelodysplastic syndrome Second or subsequent allogeneic HCT after relapse of a myeloid malignancy Chronic myelomonocytic leukemia Myeloprolipherative neoplasms, unclassifiable\n\n\\- No severe concurrent illness\n\nExclusion Criteria:\n\n* Patients with indication for allogeneic hematopoietic stem cell transplantation\n* Patients with \\\u003C10\u002F10 HLA-matched related or unrelated donor available. The donor and recipient must be identical by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1.\n* Peripheral blood stem cells or bone marrow as a graft source\n* Diagnosis:\n\nAcute myeloid leukemia Chronic myeloid leukemia, Ph+ Myelodysplastic Syndromes Myeloprolipherative neoplasms - High-risk disease defined as: Acute myeloid leukemia: \\>5% of clonal blasts in bone marrow despite adequate previous induction therapy or allogeneic stem cell transplantation Myelodysplastic Syndrome: \\>5% of blasts despite previous therapy Myeloid malignancy with with -7 or complex karyotype, or p53 mutation regardless of blast count in bone marrow Treatment-related myelodysplastic syndrome Second or subsequent allogeneic HCT after relapse of a myeloid malignancy Chronic myelomonocytic leukemia Myeloprolipherative neoplasms, unclassifiable\n\n\\- No severe concurrent illness","70 Years",{"count":112,"type":21},60,[60],"Optimization of bendamustine-containg graft-versus-host disease (GVHD) prophylaxis to reduce the incidence of secondary haemophagocytic lymphohistiocytosis and GVHD",[116,117,118,119,30],"Acute Myeloid Leukemia (AML)","Chronic Myeloid Leukemia","Myelodysplastic Syndromes (MDS)","Myeloprolipherative Neoplsm",[121,122,123,124,125],"Post-transplantation cyclophosphamide","Post-transplantation bendamustine","graft-versus-host disease","abatacept","ruxolitinib","2025-11-16",{"date":128,"type":41},"2025-11-20",{"date":130,"type":41},"2025-05-10",{"date":132,"type":21},"2026-12-10",{"name":134,"class":48},"St. Petersburg State Pavlov Medical University"]